Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 3/20 | 0.38 |
| ▸ | PDE1A | P54750 | 3/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470130 | 0.75 | CHEK1 (0.46) | CHEK1 | |
| SCHEMBL5465852 | 0.75 | CHEK1 (0.38) | CHEK1L3MBTL1NOTUMPDE5APDE1A | |
| SCHEMBL5478059 | 0.75 | CHEK1 (0.45) | CHEK1 | |
| SCHEMBL5475521 | 0.73 | CHEK1 (0.52) | CHEK1NOTUM | |
| SCHEMBL14492478 | 0.73 | CHEK1 (0.52) | CHEK1GRM2 | |
| SCHEMBL560634 | 0.72 | MAPT (0.54) | CHEK1SMN1; SMN2ADORA1PDE1APDE1B | |
| SCHEMBL5470155 | 0.71 | CHEK1 (0.70) | CHEK1GRM2RAB9A | |
| SCHEMBL5483336 | 0.70 | CHEK1 (0.68) | CHEK1GRM2RAB9A | |
| SCHEMBL5475307 | 0.70 | ADORA1 (0.45) | CHEK1GRM2ADORA1PDE5APDE1A | |
| SCHEMBL5470798 | 0.70 | CHEK1 (1.00) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0027002-B1 | 1,2,4-TRIAZOLO (4,3-A) QUINOLIN-1 (2H)-ONES AND THE COMPOUNDS FOR USE AS PHARMACEUTICALS | Bristol-Myers Company (US) | 1984-07-11 | — | — | EP | claimed |
| US-20150175603-A1 | TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-06-25 | — | — | US | disclosed |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| EP-0027002-B1 | 1,2,4-TRIAZOLO (4,3-A) QUINOLIN-1 (2H)-ONES AND THE COMPOUNDS FOR USE AS PHARMACEUTICALS | Bristol-Myers Company (US) | 1984-07-11 | — | — | EP | disclosed |
| EP-0027002-B1 | 1,2,4-TRIAZOLO (4,3-A) QUINOLIN-1 (2H)-ONES AND THE COMPOUNDS FOR USE AS PHARMACEUTICALS | Bristol-Myers Company (US) | 1984-07-11 | — | — | EP | disclosed |
| EP-0027002-A1 | 1,2,4-Triazolo (4,3-a) quinolin-1 (2H)-ones and the compounds for use as pharmaceuticals | Bristol-Myers Company (US) | 1981-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | CHEK1 4162/4885SMN1; SMN2 4594/4885PBRM1 4396/4885 |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | CHEK1 4162/4885SMN1; SMN2 4594/4885PBRM1 4396/4885 |
| US-20150175603-A1 | TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | KAT2A, KAT2B, KAT7 | CHEK1 2342/4885SMN1; SMN2 2015/4885PBRM1 1944/4885 |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | CHEK1 13/4885SMN1; SMN2 4251/4885PBRM1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.